MLICM
RVNC

Metropolitan Life Insurance Company (MetLife)’s Revance Therapeutics, Inc. RVNC Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,633
Closed -$17.9K – 2224
2024
Q1 		$17.9K Sell
3,633
-1,199
-25% -$7.1K ﹤0.01% 1917
2023
Q4 		$42.5K Hold
4,832
– – ﹤0.01% 1536
2023
Q3 		$55.4K Buy
4,832
+275
+6% +$5.29K ﹤0.01% 1347
2023
Q2 		$115K Buy
4,557
+191
+4% +$5.95K 0.01% 947
2023
Q1 		$141K Sell
4,366
-626
-13% -$19.5K 0.01% 822
2022
Q4 		$92.2K Buy
4,992
+677
+16% +$15.5K ﹤0.01% 1096
2022
Q3 		$117K Sell
4,315
-459
-10% -$9.31K 0.01% 936
2022
Q2 		$66K Hold
4,774
– – ﹤0.01% 1323
2022
Q1 		$93.1K Sell
4,774
-12,182
-72% -$185K ﹤0.01% 1237
2021
Q4 		$277K Sell
16,956
-2,700
-14% -$45K ﹤0.01% 1789
2021
Q3 		$548K Buy
19,656
+439
+2% +$12.5K 0.01% 1398
2021
Q2 		$570K Buy
19,217
+2,257
+13% +$65.1K 0.01% 1443
2021
Q1 		$474K Sell
16,960
-602
-3% -$16.7K 0.01% 1454
2020
Q4 		$498K Hold
17,562
– – 0.01% 1353
2020
Q3 		$442K Hold
17,562
– – 0.01% 1298
2020
Q2 		$429K Buy
17,562
+1,976
+13% +$39K 0.01% 1327
2020
Q1 		$231K Buy
15,586
+1,299
+9% +$26.9K ﹤0.01% 1512
2019
Q4 		$232K Sell
14,287
-1,851
-11% -$28.7K ﹤0.01% 1810
2019
Q3 		$210K Buy
16,138
+4,702
+41% +$57.5K ﹤0.01% 1842
2019
Q2 		$148K Hold
11,436
– – ﹤0.01% 2091
2019
Q1 		$180K Buy
11,436
+561
+5% +$9.73K ﹤0.01% 1963
2018
Q4 		$219K Hold
10,875
– – ﹤0.01% 1759
2018
Q3 		$270K Hold
10,875
– – ﹤0.01% 1800
2018
Q2 		$299K Buy
10,875
+2,232
+26% +$67.1K ﹤0.01% 1668
2018
Q1 		$266K Buy
8,643
+1,106
+15% +$35.6K ﹤0.01% 1702
2017
Q4 		$269K Sell
7,537
-8,085
-52% -$232K ﹤0.01% 1717
2017
Q3 		$430K Hold
15,622
– – ﹤0.01% 1784
2017
Q2 		$412K Buy
15,622
+2,323
+17% +$51.8K ﹤0.01% 1844
2017
Q1 		$277K Hold
13,299
– – ﹤0.01% 2064
2016
Q4 		$275K Hold
13,299
– – ﹤0.01% 2149
2016
Q3 		$216K Hold
13,299
– – ﹤0.01% 2292
2016
Q2 		$181K Hold
13,299
– – ﹤0.01% 2386
2016
Q1 		$232K Hold
13,299
– – ﹤0.01% 2085
2015
Q4 		$454K Buy
13,299
+2,190
+20% +$75.9K ﹤0.01% 1680
2015
Q3 		$331K Hold
11,109
– – ﹤0.01% 1913
2015
Q2 		$355K Buy
+11,109
New +$286K ﹤0.01% 1994
2014
Q4 		– Sell
-7,262
Closed -$140K – 2675
2014
Q3 		$140K Buy
7,262
+2,823
+64% +$73.6K ﹤0.01% 2567
2014
Q2 		$151K Sell
4,439
-4,391
-50% -$138K ﹤0.01% 2649
2014
Q1 		$278K Buy
+8,830
New +$276K ﹤0.01% 2243

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s RVNC Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 3,633 shares — an estimated $17.9K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in RVNC in Q1 2014 and held it in 39 quarters. The position peaked at $570K in Q2 2021. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,633 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $17.9K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 39 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Revance Therapeutics, Inc. position peaked at $570K in Q2 2021.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.